Join us November 19th from 2:00-3:00 pm Eastern to learn about a new clinical trial testing tovorafenib and rituximab in HCL. Dr. Seema Bhat, the lead investigator for the trial, will discuss the trial's objectives and answer questions from patients and families. Dr. Bhat is from the Ohio State University Comprehensive Cancer Center.
Clinical Trials Webinar: Tovorafenib in HCL
Thursday, November 19th, 2:00-3:00 pm Eastern
(11:00 am - 12 pm Pacific; 1:00-2:00 pm Central)
What drugs are being tested in this trial?
Tovorafenib is a drug used to treat pediatric cancer that is being studied in other types of cancer, including HCL. Tovorafenib blocks certain proteins made by the mutated BRAF gene.
Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some cancer cells.
Registration is required! Sign up for your spot. >>
The webinar will be recorded and a formatted recording and transcript will be published on the HCLF website about a week after the presentation.